Save the Date
November 18 – 19, 2020 • Harvard Medical School, Boston, MA
The 16th Annual Personalized Medicine Conference at Harvard Medical School will explore the science, business, and policy issues shaping the landscape and outlook for personalized medicine.
-
“With gene therapies, cell-based regenerative medicine, more targeted therapies, and the introduction of better tools for delivering therapies from digital health apps to artificial intelligence to next-generation sequencing, we’re living in an age of momentous progress and rapid cycles of innovation.
”— Scott Gottlieb, M.D., Resident Fellow, American Enterprise Institute -
“With new biomarkers coming on line, we probably will be able to diagnose much better who will respond best to therapy. That means we have to develop drugs and diagnostics together.
”— Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson -
“It is important that the research, medical, and pharmaceutical communities collaborate to maintain momentum in personalized medicine so that we are able to deliver cutting-edge care and clinical trial opportunities to all patients.
”— Carl June, M.D., Richard W. Vague Professor in Immunotherapy, University of Pennsylvania
2019 Speakers
Bonnie J. Addario
Co-Founder, Chair
GO2 Foundation for Lung Cancer
Scott Gottlieb, M.D.
Resident Fellow
American Enterprise Institute
Carl June, M.D.
Richard W. Vague Professor in Immunotherapy
University of Pennsylvania
Nancy Mendelsohn, M.D.
Chief Medical Officer, Special Needs Initiative
UnitedHealth Group
Michael Pellini, M.D., M.B.A.
Managing Partner
Section 32
Steven Shak, M.D.
Chief Scientific Officer
Genomic Health
Kenna R. Mills Shaw, Ph.D.
Executive Director
MD Anderson Institute for Personalized Cancer Therapy
Paul Stoffels, M.D.
Vice Chairman, Executive Committee; Chief Scientific Officer
Johnson & Johnson
Meg Tirrell
Reporter
CNBC
2019 Sponsors
